6ER-024 Comparison of reductions in monthly migraine days between new small molecule cgrp receptor a...
6ER-024 Comparison of reductions in monthly migraine days between new small molecule cgrp receptor antagonists (gepants) and monoclonal antibodies targeting cgrp/cgrp receptor
About this item
Full title
Author / Creator
Publisher
London: British Medical Journal Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
London: British Medical Journal Publishing Group
Subjects
More information
Scope and Contents
Contents
Background and ImportanceMigraine is characterised by repeated headache attacks lasting hours or days and usually accompanied by other associated symptoms. According to the International Headache Society, it can be classified into migraine with aura, without aura and chronic migraine. A target pathway to treat or prevent migraine is the calcitonin...
Alternative Titles
Full title
6ER-024 Comparison of reductions in monthly migraine days between new small molecule cgrp receptor antagonists (gepants) and monoclonal antibodies targeting cgrp/cgrp receptor
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2789921341
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2789921341
Other Identifiers
ISSN
2047-9956
E-ISSN
2047-9964
DOI
10.1136/ejhpharm-2023-eahp.347
